Dr. McCarthy joined CytomX in December 2010 and has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto) Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium he joined SGX Pharmaceuticals where he spearheaded a wide range of large pharma partnerships as Vice President Business Development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006 (NASDAQ: SGXP). Immediately prior to joining CytomX Dr. McCarthy was a transactional partner at Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies including Afferent Pharmaceuticals (acquired by Merck), TyRx (acquired by Medtronic), Lumena (acquired by Shire), CoLucid (NASDAQ: CLCD) and LEAD Therapeutics, the originator of talazoparib, now a Phase 3 product candidate in the Medivation pipeline. Dr. McCarthy is an author on multiple peer-reviewed scientific publications, issued patents and filed patent applications. He received his B.Sc. in biochemistry and pharmacology at King’s College, University of London; his M.B.A. from the Rady School of Management at UC San Diego; and a D. Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy is a Board member of the California Life Sciences Association.